Oculis licenses therapy that may prevent optic nerve, retina damage
Click Here to Manage Email Alerts
Oculis and Accure Therapeutics have agreed to terms for Oculis to license ACT-01, which is under investigation for the prevention of damage to the optic nerve and retina, according to a press release.
ACT-01, which will be renamed OCS-05, “is a first-in-class small molecule with neuroprotective activity that has shown positive results in animal models of neuroinflammation
and neurodegeneration,” the release said. It is under evaluation in the phase 2a ACUITY study, which is investigating safety and tolerability in patients with acute optic neuritis.
“We are excited about this agreement as it combines Oculis’ ophthalmology expertise with Accure’s unique neuroprotective approach to help transform the treatment of neurodegenerative diseases in ophthalmology,” Riad Sherif, MD, CEO of Oculis, said in the release.
Financial terms of the deal were not disclosed.
Read more about
Click Here to Manage Email Alerts